CS02A: Arterial Wound

Gender
Male
Age
60
CellerateRX Prodcut Used
Gel and Powder
Diagnosis
Wound dehisance, cellulitus of the foot, non-healing surgical wound, atherosclerosis with rest pain.


Initial Visit 6-3-04

Post Debridement

Treatment: Local wound care, antibiotics, and evaluation for possible revascularization. The ABI on the right foot for the dorsalis pedis artery was 0.36 and the ABI on the posterior tibial artery was 0.46. CellerateRX and a silver product covered with a non-adherent dressing were applied and ordered for every other day application.


6-8-04

6-17-04


The wound VAC was started on June 8, 2004. CellerateRX and a silver product were applied to the wound prior to application of the black foam sponge. Arteriography was performed on June 9, 2004 with good results.

7-16-04

7-28-04


8-4-04

The CellerateRX powder had not been removed by the patient at the time of dressing changes and was minimally disrupted at the time of the weekly wound inspection. Red spots were visualized in the gelatinous covering of the wound which were suggestive of granulation tissue.

To determine the nature of the gelatinous covering of the wound, it was removed and sent to pathology. The pathology report read, "The segments of fibrino-collagenous eosinophilic material demonstrate a heavy inflammatory cell infiltrate consisting of polymorphonuclear leukocytes, monocytes, as well as some lymphoid cells. Ingrowth into this material by small vessels and fibroblasts are also evident."


8-25-04

The wound is closed with a thin film of epithelial tissue and callous at the edges. The patient is discharged from the physician's care.


Conclusion: Achieved closure of complex wound with good wound care and the use of CellerateRX.

 

 

 

   

Pharma Technology International, LLC • 2275 Swallow Hill Road • Building 1200 • Pittsburgh, PA 15220 • USA
412-722-0250 • Fax 412-279-7665
©2010 • All Rights Reserved